# Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects

> **NCT00317109** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 168 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** Tritanrix™- HepB
- **BIOLOGICAL:** Hiberix™
- **BIOLOGICAL:** Mencevax™ ACW

## Key facts

- **NCT ID:** NCT00317109
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04-19
- **Primary completion:** 2007-05-01
- **Final completion:** 2007-05-17
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00317109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00317109, "Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00317109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*